The main long-term unknowns are how often a particular cell treatment causes late tumors or unwanted tissue growth, whether cells persist or move elsewhere, and whether immune, organ, or reproductive effects emerge years later. Repeat-dose safety is another product-specific question. These are not proof that every treatment causes these harms. Some complications are already documented; what may remain uncertain is their frequency, timing, and relevance to the exact treatment offered.
FDA has received reports of tumor formation, infections, and other serious injuries after unapproved regenerative medicine products. Its warning also identifies unwanted immune responses and cells growing or forming tissue in unintended locations. Those warnings do not establish a lifetime risk percentage for a different product. Important patient and consumer information about regenerative medicine therapies

This is general information, not personal medical advice. A qualified treating physician should assess the evidence and monitoring needed for your diagnosis and proposed procedure.
Known risks and unanswered questions
Blood-forming stem cell transplantation, approved cell products, experimental interventions, and private-clinic services are not interchangeable. An approved product can still have unresolved safety questions, while an unapproved intervention may lack the evidence needed to estimate risk at all.
| Treatment | What evidence can establish | What still needs checking |
|---|---|---|
| Blood-forming stem cell transplant | NCI describes established late effects, including infertility, second cancers, cataracts, organ damage, and bone or muscle weakness. Stem cell transplant | Personal risk depends on the disease, conditioning treatment, donor source, and complications. |
| Approved cell product for its authorized indication | The product label and supporting studies describe the population, use, and safety evidence assessed. | How long patients were observed, which late events were monitored, and what further follow-up is required. |
| Investigational cell preparation in a clinical trial | The protocol and completed results can show what was measured for that preparation and patient group. | Whether follow-up is long and complete enough to address the particular delayed harm being discussed. |
| Private-clinic intervention without product approval for that use | Written product details and relevant studies can be examined; availability alone establishes neither benefit nor long-term safety. | Whether credible same-product evidence and a plan for tracking late problems exist. |
For donor blood transplants, graft-versus-host disease occurs when donor immune cells attack the recipient’s tissues. Conditioning chemotherapy or radiation also contributes to transplant complications. These risks cannot simply be assigned to a joint injection or another type of cell infusion. Stem cell transplant
In Japan, a filed regenerative medicine provision plan must be distinguished from product marketing approval. PMDA describes separate frameworks for cell-based medical practice and commercialization of regenerative medical products. A plan filing is not a substitute for product approval or evidence of lasting benefit. 0003
Which long-term questions need answers?
Late tumors and unwanted tissue growth
Ask whether the exact preparation has been assessed for abnormal growth, how patients were monitored, and how long observation continued. FDA lists both tumor formation and unintended tissue growth among concerns with illegally marketed regenerative medicine therapies. That is a reason to investigate the product, not to assume that all cell sources carry the same cancer risk. Important patient and consumer information about regenerative medicine therapies
The unresolved question may be the incidence of a rare late event rather than whether abnormal growth is possible. A study with no reported tumors cannot establish zero lifetime risk, especially if it was small or observation ended before the period of concern.
Cell persistence and location
Whether cells survive, where they travel, and what they become are separate questions. FDA identifies movement to another part of the body and formation of unintended tissue as safety concerns for unapproved products. Important patient and consumer information about regenerative medicine therapies
Ask what evidence tracks the administered cells for the proposed route. Symptom improvement does not establish that cells survived, reached a target organ, or permanently repaired tissue. Conversely, lack of human tracking data is not proof that the cells persist indefinitely or cause delayed injury.
Lasting immune effects
FDA’s concerns include unwanted inflammatory or immune responses. These should not be confused with transplant-specific graft-versus-host disease. Important patient and consumer information about regenerative medicine therapies
For the proposed treatment, ask whether monitoring covers persistent inflammation or immune responses after repeated exposure. Donor-derived and patient-derived preparations need separate assessment. The absence of an immediate infusion reaction does not answer whether a later immune problem can occur.
Infection and its lasting consequences
Infection is a documented harm, not merely a theoretical long-term unknown. A 2018 CDC investigation described 12 patients hospitalized with infections after injections or infusions of contaminated, unapproved umbilical cord blood-derived products in the United States. Reported infections included bloodstream and joint infections and epidural abscesses. These findings concern a specific outbreak, not a complication rate for all stem cell treatments. Mm6750a5.htm
The longer-term questions are whether an affected patient has lasting damage and whether the provider can identify and follow everyone exposed to a problematic batch. Ask for the product and batch identifiers, manufacturing facility, release-testing information, and a route for reporting complications. Do not treat an infection detected soon after treatment as evidence of a newly emerging effect years later.
Repeat dosing and cumulative exposure
Safety evidence for one administration does not automatically cover repeated doses, higher doses, or a different route. Ask whether the proposed schedule was actually studied and whether adverse events were followed after the final dose.
When adipose-derived treatment involves liposuction, collection adds surgical risks. MedlinePlus lists complications including infection, bleeding, blood clots, fat embolism, and organ or nerve injury. These are collection-related risks, not evidence that the administered cells cause those same problems years later. 002985.htm
How long symptom relief lasts is an effectiveness question. It matters to safety if fading benefit leads to further procedures, but it should not be presented as a delayed adverse effect in itself.
Fertility, pregnancy, and organ health
NCI lists infertility and damage to the liver, kidneys, lungs, or heart among possible long-term transplant problems. That does not establish the same effects or frequencies for a non-transplant cell intervention. Stem cell transplant
Ask whether the exact product’s studies included reproductive outcomes, pregnancy exposure, relevant organ-function monitoring, and people of your age and health status. If those outcomes or populations were not studied, the evidence does not answer those questions. Missing pregnancy data should not be interpreted as reassurance about use during pregnancy or breastfeeding.
Why a reassuring study may not settle the question
There is no single follow-up duration that establishes lifetime safety for every cell product. Check the length of observation against the harm being considered, and distinguish the longest follow-up of one participant from the follow-up completed by the whole group.
- Study size: a small study has limited ability to detect rare harms.
- Missing patients: ask how many participants were still being assessed at each reported time point.
- Outcome selection: collecting pain scores is not the same as systematically checking for tumors, immune effects, or organ injury.
- Treatment match: different cell sources, manufacturing methods, doses, and administration routes cannot be treated as equivalent.
- Causation: an adverse event is a health problem observed during or after treatment; it is not automatically caused by the treatment.
Trial registration alone is not proof that a treatment works, is legally marketed, or has completed long-term safety evaluation. FDA specifically warns against interpreting a ClinicalTrials.gov listing or FDA establishment registration as evidence of lawful marketing. A study’s presence in a literature database is also not, by itself, a quality assessment. Important patient and consumer information about regenerative medicine therapies
A practical way to assess an offer
Illustrative scenario: suppose a clinic supplies a study with six months of follow-up and says the treatment is safe for the next five years. The study does not support that time extension. Ask for longer follow-up of the same preparation, how many people completed it, and which late harms were actively sought.
Using your own cells does not eliminate processing and administration risks. FDA’s warning explicitly covers unapproved products recovered from either the patient’s body or another person’s body. Important patient and consumer information about regenerative medicine therapies
Before deciding, request the following in writing:
- The cell source, product or preparation name, manufacturing method, dose, route, and applicable regulatory status.
- Studies matching your diagnosis and proposed treatment, including patient numbers, comparison groups, outcomes, and completed follow-up.
- A clear account of known adverse events, unresolved questions, and evidence for repeat dosing.
- A named clinician responsible for follow-up, the monitoring schedule, and arrangements after you return home.
- How a late problem would be investigated, where treatment and batch records are kept, and who bears additional costs.
- Established alternatives and the consequences of delaying standard care.
A written treatment and follow-up plan helps make those responsibilities explicit; it does not replace evidence. The treating physician should tailor monitoring rather than apply an unsupported universal testing schedule.
Questions about follow-up arrangements in Japan?
Ask the patient support team about appointment coordination and documents to request. Medical risk assessment and treatment decisions belong to the treating physician.
Bottom line: the unanswered question is not whether stem cells are universally safe or dangerous. It is what delayed harms have been measured for the exact intervention, what remains unmeasured, and who will monitor you. Missing long-term evidence proves neither safety nor inevitable harm.




